Form 4 for AVTX Avalo Therapeutics, Inc.

Accepted 2023-06-09 00:00:00 ET · period of report 2023-06-07 · accession 0001929354-23-000013 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2023-06-09	2023-06-07+	AVTX	Caissa Capital Management ltd.	10%	P - Purchase	$3.91	+14.4K	1.40M	+1%	+$56.4K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-06-09	P	A	5,044	$4.14	1,400,641	I See Footnote (1)	—	—	(F4) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.01 to $4.3, inclusive. (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
2	Common	Common Stock	2023-06-07	P	A	2,984	$3.49	1,389,199	I See Footnote (1)	—	—	(F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.90 to $3.6, inclusive. (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
3	Common	Common Stock	2023-06-08	P	A	6,398	$3.93	1,395,597	I See Footnote (1)	—	—	(F3) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.775 to $4.22, inclusive. (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.